“A hot topic”: TTR amyloidosis gets its moment to shine at ESC 2024

n transthyretin amyloidosis (ATTR), the liver produces an abnormal transthyretin (TTR) protein, which aggregates into amyloid fibrils that accumulate in peripheral nerves and the heart. Over time, this can lead to progressive cardiomyopathy (ATTR-CM), heart failure (HF), and premature mortality. At the recent meeting of the ESC there was much excitement and enthusiasm about ATTR-CM, largely inspired by the HELIOS-B trial of vutrisiran, an RNA interference (RNAi) agent that, if approved, would become only the second medication indicated for ATTR-CM. This report reviews the most relevant insights from the meeting into the diagnosis and management of ATTR-CM, with expert commentary on their relevance and implications for Canadian clinicians.